Scalper1 News
Medical giant Johnson & Johnson (JNJ) beat Wall Street’s Q1 estimates Tuesday and raised its operating guidance, but it said foreign-exchange headwinds are getting even stronger than it expected. On a reported basis, J&J’s sales dropped 4.1% from the year-earlier quarter to $17.4 billion, modestly beating analysts’ consensus of $17.3 billion. Earnings declined 4.3% to $1.56 a share, beating estimates by 2 cents. On a constant-currency basis, sales Scalper1 News
Scalper1 News